Match!
H. Bryan Brewer
MedStar Washington Hospital Center
237Publications
67H-index
53.3kCitations
Publications 237
Newest
#1Ron Waksman (MedStar Washington Hospital Center)H-Index: 75
#2Carlo Di Mario (UniFI: University of Florence)H-Index: 82
Last.Christopher KimH-Index: 1
view all 10 authors...
Summary Background Near-infrared spectroscopy (NIRS) intravascular ultrasound imaging can detect lipid-rich plaques (LRPs). LRPs are associated with acute coronary syndromes or myocardial infarction, which can result in revascularisation or cardiac death. In this study, we aimed to establish the relationship between LRPs detected by NIRS-intravascular ultrasound imaging at unstented sites and subsequent coronary events from new culprit lesions. Methods In this prospective, cohort study (LRP), pa...
#1Robert S. RosensonH-Index: 59
#2H. Bryan BrewerH-Index: 67
Last.Frank M. SacksH-Index: 109
view all 10 authors...
HDL-cholesterol levels in plasma predict the risk of cardiovascular disease, but a direct causal role for HDL in cardiovascular disease remains controversial. In this Review, Rosenson et al. discuss the opportunities afforded by an integrated approach that combines human genetic studies with systems biology to understand the complex metabolism of HDL and its potential atheroprotective properties.
#1A.M. LincoffH-Index: 97
#2Stephen J. NichollsH-Index: 53
Last.Gilles Montalescot (Paris IV: Paris-Sorbonne University)H-Index: 32
view all 10 authors...
BackgroundThe cholesteryl ester transfer protein inhibitor evacetrapib substantially raises the high-density lipoprotein (HDL) cholesterol level, reduces the low-density lipoprotein (LDL) cholesterol level, and enhances cellular cholesterol efflux capacity. We sought to determine the effect of evacetrapib on major adverse cardiovascular outcomes in patients with high-risk vascular disease. MethodsIn a multicenter, randomized, double-blind, placebo-controlled phase 3 trial, we enrolled 12,092 pat...
#1Stephen J. Nicholls (University of Adelaide)H-Index: 53
#2Giacomo Ruotolo (Eli Lilly and Company)H-Index: 10
Last.Steven E. Nissen (Cleveland Clinic)H-Index: 86
view all 9 authors...
Background Potent CETP inhibitors reduce plasma concentrations of atherogenic lipoprotein biomarkers of cardiovascular risk. Objectives To evaluate the effects of the cholesteryl ester transfer protein (CETP) inhibitor evacetrapib, as monotherapy or with statins, on atherogenic apolipoprotein B (apoB)–containing lipoproteins in mildly hypercholesterolemic patients. Methods VLDL and LDL particle concentrations and sizes (using nuclear magnetic resonance spectroscopy) and lipoprotein(a) concentrat...
#1Michael J. Lipinski (MedStar Washington Hospital Center)H-Index: 29
#2Umberto Benedetto (BRI: Bristol Royal Infirmary)H-Index: 20
Last.Ron Waksman (MedStar Washington Hospital Center)H-Index: 75
view all 9 authors...
Aims We performed a network meta-analysis of randomized controlled trials (RCTs) in patients with primary hypercholesterolaemia to compare the impact of proprotein convertase subtilisin-kexin type 9 serine protease (PCSK9) inhibitors with placebo and ezetimibe on lipid levels and outcomes. Methods and results MEDLINE/PubMed, Cochrane CENTRAL, and ClinicalTrials.gov were searched for RCTs assessing PCSK9 inhibitors vs. other therapies in patients with primary hypercholesterolaemia. Network meta-a...
#1Stephen J. NichollsH-Index: 53
#2R. Puri Mbbs (Cleveland Clinic)H-Index: 32
Last.Yu KataokaH-Index: 24
view all 10 authors...
Background Bromodomain and extra-terminal (BET) proteins regulate transcription of lipoprotein and inflammatory factors implicated in atherosclerosis. The impact of BET inhibition on atherosclerosis progression is unknown.
#1Robert S. Rosenson (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 59
#2H. Bryan Brewer (MedStar Washington Hospital Center)H-Index: 67
Last.Nancy R. Webb (UK: University of Kentucky)H-Index: 32
view all 9 authors...
High-density lipoproteins (HDLs) have various antiatherosclerotic effects; however, inflammation can cause HDL to become dysfunctional, which impairs its protective properties. In this Review, Rosenson and colleagues discuss the mechanisms by which HDL and apolipoprotein A-I protect against atherosclerosis, and how diagnostic and therapeutic approaches might target these proteins when they become dysfunctional.
#1Stephen J. Nicholls (University of Adelaide)H-Index: 53
#2A.M. Lincoff (Cleveland Clinic)H-Index: 97
Last.Daniel J. Rader (UPenn: University of Pennsylvania)H-Index: 134
view all 10 authors...
Background Potent pharmacologic inhibition of cholesteryl ester transferase protein by the investigational agent evacetrapib increases high-density lipoprotein cholesterol by 54% to 129%, reduces low-density lipoprotein cholesterol by 14% to 36%, and enhances cellular cholesterol efflux capacity. The ACCELERATE trial examines whether the addition of evacetrapib to standard medical therapy reduces the risk of cardiovascular (CV) morbidity and mortality in patients with high-risk vascular disease....
#1Michael J. LipinskiH-Index: 29
Last.Ron WaksmanH-Index: 75
view all 7 authors...
Introduction: We performed a network meta-analysis of randomized controlled trials (RCTs) in patients with primary hypercholesterolemia to compare the impact of PCSK9 inhibitors with placebo and ezetimibe on lipid levels and outcomes. Hypothesis: PCSK9 inhibitors will significantly lower LDL-C greater than ezetimibe and improve outcomes. Methods: MEDLINE/PubMed, Cochrane CENTRAL, and ClinicalTrials.gov were searched for RCTs assessing PCSK9 inhibitors versus other therapies in patients with prim...
#1Stephen J. Nicholls (University of Adelaide)H-Index: 53
#2Giacomo Ruotolo (Eli Lilly and Company)H-Index: 10
Last.Daniel J. Rader (Cardiovascular Institute of the South)H-Index: 134
view all 9 authors...
Abstract Background Potent cholesteryl ester transfer protein (CETP) inhibitors have been shown to substantially increase high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A-I levels as monotherapy and combined with statins. However, data on the effects of this class of drugs on macrophage cholesterol efflux capacity (CEC), a functional assay that characterizes a key step in the process of reverse cholesterol transport, are limited. Objectives This study assessed the impact of evac...
12345678910